"Significant Unmet Needs" Remain in Hepatitis C

December 22, 2016

December 22, 2016

Although recent years have seen a revolution in the hepatitis C space, as interferon-free direct-acting antiviral (DAA) combination therapies have started replacing interferon-based therapies, a number of considerable unmet needs remain, according GBI Research.

The company’s latest report emphasises that although the proportion of hepatitis C patients who do not respond to or cannot tolerate DAA combination therapies is small, as over 90% can now be cured within 3–6 months, a failure rate of even 5% may still leave up to 10 million people with unmet needs due to the high prevalence. In addition, it is estimated that 1-2% of people who reach a sustained virologic response may experience a subsequent relapse over a 4-5 year period.

The need to develop drugs for non-responsive and relapsing patients means the hepatitis C space is a commercially attractive one, reports GBI. Currently, the hepatitis C pipeline is relatively active, with 198 products in development, and differs significantly from the market landscape, which is dominated by interferon immune mediators and ribavirin products.

See the report here.
 

Related Content:

Technology